Shopping Cart

Your shopping cart is currently empty

Emricasan

Name: Emricasan
Brand: TargetMol
SKU: T6826
Price: 50 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T6826Cas No. 254750-02-2

Alias PF 03491390, IDN-6556

Emricasan (IDN-6556) is a pan-caspase inhibitor with irreversible properties. Emricasan has anti-inflammatory and anti-apoptotic activity and can be used in the treatment of infections and liver failure, etc. Emricasan also inhibits Zika virus infections.

Emricasan

Copy Product Info

🥰Excellent

Purity: 99%

Catalog No. T6826Alias PF 03491390, IDN-6556Cas No. 254750-02-2

Pack Size	Price	USA Warehouse	Global Warehouse
2 mg	$50	In Stock	In Stock
5 mg	$83	In Stock	In Stock
10 mg	$140	In Stock	In Stock
25 mg	$253	In Stock	In Stock
50 mg	$419	In Stock	In Stock
100 mg	$617	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$103	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99%

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	Emricasan (IDN-6556) is a pan-caspase inhibitor with irreversible properties. Emricasan has anti-inflammatory and anti-apoptotic activity and can be used in the treatment of infections and liver failure, etc. Emricasan also inhibits Zika virus infections.
Targets&IC50	Caspase-8:0.4 nM, THP-1 cells:0.27 μM, Caspase-3:0.31 nM, JFas cells:0.025 μM
In vitro	METHODS: Primary rat cirrhotic hepatocytes were treated with Emricasan (50 µM) for 24 h, and mRNA expression levels were measured. RESULTS: Emricasan directly improved the expression of hepatocyte-specific markers. [1] METHODS: Human cervical cancer cells HeLa were pretreated with Emricasan (10 µM) for 1 h, then treated with vincristine (20 nM) for 44 h. Cell death was detected by Flow Cytometry. RESULTS: Emricasan eliminated 95% of vincristine-mediated cell death. [2]
In vivo	METHODS: To study the effects on chronic liver disease, Emricasan (10 mg/kg, 0.9% dimethylcarboxycellulose) was administered orally once daily for seven days to rats with advanced cirrhosis due to chronic CCl4 administration. RESULTS: Emricasan ameliorated hepatic sinusoidal microvascular dysfunction in cirrhotic patients, resulting in significant improvement in fibrosis, portal hypertension and liver function. [1] METHODS: To investigate the effects on cirrhosis, Emricasan (10 mg/kg) was administered intraperitoneally once daily for 10-20 days to C57BL/6 mice with secondary biliary cirrhosis induced by bile duct ligation (BDL). RESULTS: Emricasan treatment improved survival and portal hypertension (PHT) in a mouse model of long-term BDL. [3]
Cell Research	Astrocytes are mock-infected, treated with DMSO or treated with 2 μM niclosamide, 92 μM PHA-690509, 9 μM emricasan, or a combination of 92 μM PHA-690509 and 9 μM emricasan for 1 h before infection with PRVABC59 (MOI = 0.5). Cells are fixed 24 h after infection and stained for ZIKVE and nuclei.(Only for Reference)
Synonyms	PF 03491390, IDN-6556

Chemical Properties

Molecular Weight	569.5
Formula	C₂₆H₂₇F₄N₃O₇
Cas No.	254750-02-2
Smiles	C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F
Relative Density.	1.386 g/cm3

Storage & Solubility Information

Storage

In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

H2O: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 257.5 mg/mL (452.15 mM), Sonication is recommended.

Ethanol: 93 mg/mL (163.3 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (8.78 mM), Solution.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	1.7559 mL	8.7796 mL	17.5593 mL	87.7963 mL
5 mM	0.3512 mL	1.7559 mL	3.5119 mL	17.5593 mL
10 mM	0.1756 mL	0.8780 mL	1.7559 mL	8.7796 mL
20 mM	0.0878 mL	0.4390 mL	0.8780 mL	4.3898 mL
50 mM	0.0351 mL	0.1756 mL	0.3512 mL	1.7559 mL
100 mM	0.0176 mL	0.0878 mL	0.1756 mL	0.8780 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc